Dr. Shakeel Aslam
Chief Medical Officer, Telfair
Replay available
Talphera, Inc. (TLPH) Q4 2025 Earnings Call
Talphera, Inc. (NASDAQ: TLPH) Q4 2025 earnings conference call, held 2026-03-23. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Yuan Z
Analyst, B. Riley Securities
Dr. Teixeira
Associate Professor of Nephrology, Pulmonary Critical Care, and Sleep Medicine at University of New Mexico; Director of Acute Dialysis and CRRT Programs, UNMH
Dr. McMahon
Associate Professor of Medicine at Medical University of South Carolina; Director of CRRT Program, MUSC
Vince Angotti
Chief Executive Officer, Telfair
Ed Ars
Analyst, West Park Capital
Jim Malloy
Analyst, AGP
Naz Rahman
Analyst, Maxim Group
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Talphera, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.419 -- 00:00:05.447 Good morning, everyone, and welcome to the Telfair Virtual Analyst and Investor event. 00:00:05.447 -- 00:00:08.111 At this time, all attendees are in a listen-only mode. 00:00:08.111 -- 00:00:11.536 A question and answer session will follow the formal presentations. 00:00:11.536 -- 00:00:15.483 As a reminder, this call is being recorded and a replay will be made available on the 00:00:15.483 -- 00:00:18.427 Telfair website following the conclusion of the event. 00:00:18.427 -- 00:00:23.114 I'd now like to turn the call over to Vince Angotti, Chief Executive Officer at Telfair. 00:00:23.114 -- 00:00:24.657 Please go ahead. 00:00:24.657 -- 00:00:29.225 Thank you, Tara. And good morning, everyone, and thank you for joining our event today. 00:00:29.225 -- 00:00:34.354 I'm excited to be joined by Dr. Shaquille Aslam, Telfer's chief medical officer, 00:00:34.354 -- 00:00:39.442 and two key experts in continuous renal replacement therapy, who are also 00:00:39.442 -- 00:00:44.370 principal investigators in our NEFRO CRRT registrational study. 00:00:44.370 -- 00:00:48.377 Through their experience and expertise, we hope to provide you with a better understanding 00:00:48.377 -- 00:00:50.302 of CRRT 00:00:50.302 -- 00:00:54.588 the anticoagulants currently being used during CRRT, 00:00:54.588 -- 00:01:00.977 and how these experts see Nifamistat potentially filling an unmet need for anticoagulation 00:01:00.977 -- 00:01:04.459 of the CRRT circuit. 00:01:04.723 -- 00:01:08.548 Our agenda will specifically include, first, 00:01:08.548 -- 00:01:14.557 a very brief business update so we can move quickly to our key expert discussion, 00:01:14.557 -- 00:01:19.020 followed by Q&A and closing remarks. 00:01:19.327 -- 00:01:23.391 Before we begin, I...